A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to generate protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% protection when vaccinated four weeks before birth
- Antibodies from the mother passed through the placenta safeguard newborns from birth
- Protection achievable with 2-week gap before early delivery
- Vaccination during the third trimester still offers meaningful protection for infants
Strong evidence from recent research
The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation conducted across England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s real-world impact. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scope of this study offers healthcare professionals and expectant parents with confidence in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results reveal a striking picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the vast majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s essential role in preventing serious illness in newborns. The drop in hospital admissions above 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospital admissions. The large sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology measured real-world outcomes rather than experimental conditions, providing tangible evidence of how the vaccine works when given across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the hazards
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection triggers deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to feed and breathe properly. Parents frequently observe their babies visibly struggling, their chests rising whilst they work to get adequate oxygen into their damaged lungs. Whilst most newborns improve through clinical support, a modest yet notable proportion perish from RSV complications each year, making vaccination as prevention a critical public health priority for protecting the youngest and most vulnerable people in our communities.
- RSV produces inflammation in lungs, resulting in serious respiratory problems in infants
- Half of all newborns acquire the virus during their first few months alive
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- Few babies die from RSV complications annually in the UK
Take-up rates and professional guidance
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the value of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that the timing is essential for guaranteeing newborns receive the maximum immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers nearly 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies through the placenta.
The communication from public health bodies remains clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This flexible approach recognises the practical demands of pregnancy whilst maintaining strong safeguarding for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Certain regions have achieved higher vaccination coverage among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These geographical variations reflect variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates consistently strong protection regardless of geographical location.
- NHS trusts deploying multiple messaging strategies to engage with pregnant women
- Inconsistencies across regions in vaccine uptake rates in different parts of England necessitate strategic intervention
- Community health services modifying schemes to align with local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness delivers concrete gains for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this protective measure, the 80% drop in admissions means thousands of infants shielded from serious illness. Parents no longer face the upsetting situation of watching their newborns gasping for air or struggle to eat, symptoms that characterise serious RSV disease. The vaccine has substantially transformed the landscape of neonatal lung health, offering expectant mothers a active means to shield their most vulnerable children during those vital initial period.
For families like that of Malachi, whose acute RSV infection resulted in devastating brain damage, the vaccine’s introduction carries deep personal significance. His mother’s advocacy for the jab emphasises the life-altering consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to pregnant women navigating their late pregnancy, converting what was once an unavoidable seasonal threat into a manageable health risk.